REBEC

Go to main content [1]
Go to main menu [2]
Enable hight contrast [3]

-

-

-

-

-

Public trial

BEM Program

Date of registration: 07/13/2021 ^(mm/dd/yyyy)
Last approval date : 07/13/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Inspiratory Muscle Training in COVID-19 patients after hospital discharge

Date of registration: 07/12/2021 ^(mm/dd/yyyy)
Last approval date : 07/12/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Neuromodulation of the vagus nerve at the auricular level and its safety, feasibility and functional assessment in patients with heart failure

Date of registration: 07/09/2021 ^(mm/dd/yyyy)
Last approval date : 07/09/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Physical activity and physical inactivity in children during the Coronavirus pandemic

Date of registration: 05/02/2021 ^(mm/dd/yyyy)
Last approval date : 07/07/2021 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Observational

Evaluation of a new substance (isobutylamido thiazolyl resorcinolcream) compared to the use of hydroquinone 4% cream to treat facial blemishes

Date of registration: 10/09/2020 ^(mm/dd/yyyy)
Last approval date : 07/07/2021 ^(mm/dd/yyyy)
Last revision: 4

Study type:

Interventional

Dique Filipéia Rehabilitation Protocol for patients with COVID-19

Date of registration: 07/07/2021 ^(mm/dd/yyyy)
Last approval date : 07/07/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of traditional Chinese medicine in postoperative pain control after wisdom extraction.

Date of registration: 07/07/2021 ^(mm/dd/yyyy)
Last approval date : 07/07/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The effect of the debriefing technique in the simulation of Basic Life Support in adults

Date of registration: 07/07/2021 ^(mm/dd/yyyy)
Last approval date : 07/07/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Use of saliva for screening patients with COVID-19

Date of registration: 07/07/2021 ^(mm/dd/yyyy)
Last approval date : 07/07/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Clinical trial with convalescent plasma for Covid-19 therapy

Date of registration: 07/07/2021 ^(mm/dd/yyyy)
Last approval date : 07/07/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Comparative study of analgesic efficacy between phosphate codeine in combination with paracetamol and oxycodone hydrochloride, after extractions of impacted lower third molars.

Date of registration: 07/07/2021 ^(mm/dd/yyyy)
Last approval date : 07/07/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation portable devices in diagnosis and follow-up of eye diseases during the COVID-19 pandemic

Date of registration: 07/06/2021 ^(mm/dd/yyyy)
Last approval date : 07/06/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of the effect of Brazilian Propolis on mouth Inflammation (Mucositis) in patients undergoing treatment for Head and Neck Cancer

Date of registration: 07/02/2021 ^(mm/dd/yyyy)
Last approval date : 07/02/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Manual Hand Osteopathic for headache patients

Date of registration: 07/01/2021 ^(mm/dd/yyyy)
Last approval date : 07/01/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of the effectiveness and cost-effectiveness of functional foods in glycemic control

Date of registration: 07/01/2021 ^(mm/dd/yyyy)
Last approval date : 07/01/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Covidreab study: pulmonary rehabilitation on physical capacity, functional capacity, and quality of life in post-covid-19: randomized, controlled double-blinded clinical trial

Date of registration: 07/01/2021 ^(mm/dd/yyyy)
Last approval date : 07/01/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of electrical stimulation on the head for patients with stress after a traumatic event: controlled phase II clinical trial

Date of registration: 07/01/2021 ^(mm/dd/yyyy)
Last approval date : 07/01/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of Inhaled Nitric Oxide for the treatment of COVID-19

Date of registration: 09/22/2020 ^(mm/dd/yyyy)
Last approval date : 06/30/2021 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Treatment of wrist dorsal ganglion cyst. Randomized clinical trial.

Date of registration: 06/29/2021 ^(mm/dd/yyyy)
Last approval date : 06/29/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Efficacy of at-home bleaching with buccal and palatal application of teeth

Date of registration: 06/29/2021 ^(mm/dd/yyyy)
Last approval date : 06/29/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

01/15/2026

From Fragmented to Unified: How Flex Databases Is Rewiring Clinical Operations for the AI Era

01/15/2026 | Clinical Trials Arena

https://www.clinicaltrialsarena.com/excellence-in-focus/flex-databases-eclinical-platform-ai-trials/?cf-view

With pressure mounting to shorten timelines and tighten oversight, Flex Databases is betting on a single, configurable eClinical platform to help sponsors and contract research organizations (CROs) tame fragmented data, de‑risk the trial master file (eTMF), and industrialize risk‑based monitoring. Global Director of Business Development Marietta Sarkisian explains why a human‑in‑the‑loop AI “co‑pilot,” modular entry points for smaller organizations, and deep localization will be critical to keeping trials compliant, affordable, and globally connected over the next three to five years.

Clinical Trials Arena (CTA): Flex Databases has just won awards for Innovation, Product Launches, and Business Expansion. How do you interpret this recognition for the company’s current stage and direction?

Marietta Sarkisian: First of all, thank you for the acknowledgement and the awards. We are truly flattered. Second, I suppose these awards are a real reflection of the achievements we have made in recent years. We had a huge leap in our product development, and we surely keep moving forward with ambitious goals on our minds.

CTA: Sponsors and CROs still struggle with fragmented systems, slow study start-up, and eTMF inconsistencies. Which of these issues do you see as most damaging to timelines today, and why?

Marietta Sarkisian: All of the issues mentioned are actually part of a bigger puzzle, which is the absence of a robust and unified eClinical system in place. Fragmented data always appears when there is a disruption in data entry – be it due to the lack of a system or the use of multiple different systems to cover a single process.…

01/14/2026

Oncoclínicas and Hapvida NotreDame Expand Partnership in Oncology and Clinical Research

01/14/2026 | Leonardo Leão | Diário do Comércio

https://diariodocomercio.com.br/negocios/oncoclinicas-hapvida-ampliam-parceria-oncologia-pesquisa/

Cooperation foresees integration of patients into clinical studies, joint training, and expansion of research centers in strategic regions

The Minas Gerais-based medical services company Oncoclínicas&Co and the health operator Hapvida NotreDame have signed an agreement to expand their strategic partnership focused on expanding access to oncology and strengthening clinical research in Brazil. The new agreement complements the commercial partnership established between the parties in 2025, focusing on cancer treatment.

The expansion of the cooperation will allow the integration of Hapvida's oncology patients into research protocols conducted by the Minas Gerais company, creating a direct link between care and innovation.

In the first stage of the partnership, prioritization is planned for referring these patients to Oncoclínicas' clinical studies. The goal is to expand access to advanced therapies and contribute to increased recruitment in oncology research in the country.

In the second phase of the project, the collaboration takes on an even more structural dimension, with both companies advancing joint initiatives in training, scientific development, and conducting collaborative research. Furthermore, the agreement foresees the opening of new research centers in strategic locations for both organizations.

The initiative significantly expands patient recruitment and strengthens diversity in clinical studies, with a presence in practically all regions of Brazil. The expectation of the parties involved is for significant growth in the number of patients included in clinical research, a decisive…

01/14/2026

Breaking Out of AI Pilot Mode in Clinical Development

01/14/2026 | Liz Beatty, Andy Studna | Applied Clinical Trials

https://www.appliedclinicaltrialsonline.com/view/ai-pilot-mode-clinical-development

See what will distinguish sponsors that scale AI into core operations from those stuck in experimentation, and why redesigning underlying processes—not just optimizing workflows—is critical to realizing long-term value.

In a recent video interview with Applied Clinical Trials, Liz Beatty, co-founder and chief strategy officer at Inato, discussed how sponsors can balance efficiency pressures with patient access as competition for sites and patients intensifies. Beatty explained that while AI-driven tools are accelerating protocol design, feasibility, and trial operations, overreliance on a small pool of familiar sites can create bottlenecks that undermine those gains. She highlighted a shift away from historical site performance data toward real-time patient eligibility insights, enabling more accurate trial planning and inclusive site selection. Beatty also outlined how community research sites can remain competitive by using technology to demonstrate verified patient access and readiness. Looking ahead to 2026, she emphasized that sponsors able to move beyond isolated AI pilots—by redesigning underlying processes and committing to scaled change management—will be best positioned to shorten timelines and expand access to clinical trials.

The interview transcript was lightly edited for clarity.

ACT: What will distinguish pharma companies that move beyond AI pilots in 2026 from those that remain stuck in experimentation?

Beatty: Every sponsor we speak with understands the importance of AI. It has been a buzzword in 2025, and it is not going away. The question is no longer whether AI matters, but how…

01/14/2026

Cancer Trial Failures, Study Retractions Highlight Oncology Research Challenges

01/14/2025 | Emily Bader | Oncology News Central

https://www.oncologynewscentral.com/oncology/cancer-trial-failures-study-retractions-highlight-oncology-research-challenges

Recent headlines involving cancer study retractions, clinical trial failures, and shifting regulatory decisions underscore ongoing oncology research challenges.

Top Journal Retracts Cancer Study After Investigation
Nature has retracted a widely cited melanoma study after investigators found data errors that rendered some results statistically insignificant, affecting “the conclusion about therapy resistance,” according to the retraction notice. Investigators also found inconsistencies in images, source data, sample numbers, and figure labeling, although no scientific misconduct was involved.

Of the 46 authors, four agreed with the retraction, 28 disagreed, and 14 did not respond. Lead author Ashani T. Weeraratna, PhD, from Johns Hopkins University in Baltimore, said that a 2023 replication using updated methods confirmed the original findings, but Nature did not consider these results in the retraction.

Phase 3 Cancer Trial Halted as Monoclonal Antibody Combo Fails to Improve Survival
Arcus Biosciences has halted a phase 3 study testing its experimental antibodies domvanalimab and zimberelimab with chemotherapy for patients with advanced stomach and esophageal cancers. Interim data showed no survival advantage when compared with the standard treatment of nivolumab (Opdivo) plus chemotherapy, prompting an independent monitoring committee to recommend ending the…

01/13/2026

UK introduces clinical trial regulatory reforms to enhance research appeal

01/13/2026 | Salong Debbarma | Clinical Trials Arena

https://www.clinicaltrialsarena.com/news/uk-clinical-trial-regulatory-reforms/

The new rules introduce a fast-track notification route, enabling quicker starts for lower-risk trials and maintaining safety standards.

The UK has announced new clinical trial regulatory reforms to boost its appeal as a leading destination for medical research.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) reported a 9% increase in clinical trial applications between January and November 2025 compared to the same period in 2024, with notable growth in early-stage and innovative studies.

Early phase research saw the strongest gains, with trials involving healthy volunteers rising by 16%, first-in-human studies up by 5%, and initial UK-based trials increasing by 7%. The MHRA also experienced a 75% surge in scientific advice meetings as companies sought earlier guidance to optimise trial design and minimise delays.

These increases occurred under the current framework, but significant regulatory changes are set for April. The new rules will introduce a fast-track notification route for around one in five studies, enabling quicker start times for lower-risk trials while maintaining safety standards.

The MHRA will also implement a 14-day assessment process for phase I trials, aimed at expediting early testing of new medicines.

Further updates include streamlined methods for assessing overseas safety data that meet UK requirements and enhanced capabilities to evaluate computer model simulations, such as in-silico trials. These changes reflect ongoing advances in medicine development while upholding robust safety measures.

Patient involvement in research has also grown, with more than 450,000 people participating in studies…